Spondyloarthropathies: CVD prevention and statin therapy in ankylosing spondylitis

Nature Reviews Rheumatology

Volumn 12, Issue 8, 2016, Pages 441-442

  Semb, Anne Grete ^a   Rollefstad, Silvia ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALGORITHM; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INTERACTION; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; POLYPHARMACY; PRIORITY JOURNAL; RISK MANAGEMENT; SHORT SURVEY; TREATMENT OUTCOME; SPONDYLOARTHROPATHY;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING;

EID: 84976385440     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2016.103     Document Type: Short Survey

References (10)

1. van der Valk F. M., et al. Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis 2016 209176 2016).
2. Rollefstad, S., et al. Treatment to lipid targets in patients with inflammatory joint diseases in A preventive cardio-rheuma clinic. Ann. Rheum. Dis. 72, 1968-1974 (2013).
3. Semb, A. G., et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 64, 2836-2846 (2012).
4. Rollefstad, S., et al. Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study. Arthritis Rheumatol. 67, 1718-1728 (2015).
5. Ikdahl, E., et al. Sustained improvement of arterial stiffness and blood pressure after long-Term rosuvastatin treatment in patients with inflammatory joint diseases: results from the RORA AS study. PLoS ONE 11, e0153440 (2016).
6. Rollefstad, S., et al. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention. Ann. Rheum. Dis. 74, 1544-1550 (2015).
7. van Denderen, J. C., et al. Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann. Rheum. Dis. 65, 695-696 (2006).
8. Arts, E. E., et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 74, 668-674 (2015).
9. Berg, I. J., et al. Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: A cross-sectional study. J. Rheumatol. 42, 645-653 (2015).
10. Corrales, A., et al. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of A population-based study. Ann. Rheum. Dis. 73, 722-727 (2014).